Core Viewpoint - The performance of listed securities firms is expected to significantly increase in the first half of 2025, driven by the recovery of A-share market activity, positioning the brokerage sector as a leader in the current bull market [1][2]. Group 1: Performance Forecast - Nine listed brokerages have all reported expected profit increases, with a total net profit potentially exceeding 9 billion yuan, and an average growth rate of around 300% [2]. - Specific forecasts include: - Hongta Securities: Net profit of approximately 651.37 million to 696.29 million yuan, growth of 45% to 55% [3]. - Guosen Securities: Net profit of approximately 4.78 billion to 5.53 billion yuan, growth of 52% to 76% [4]. - Huaxi Securities: Net profit of approximately 445 million to 575 million yuan, growth of 1025.19% to 1353.90% [3]. - Hato Securities: Net profit of approximately 380 million yuan, growth of about 233.10% [4]. - Caida Securities: Net profit of approximately 363.34 million to 404.25 million yuan, growth of 51% to 68% [4]. - Guosheng Jinkong: Net profit of approximately 150 million to 220 million yuan, growth of 236.85% to 394.05% [4]. - Jilin Aodong: Net profit of approximately 1.236 billion to 1.289 billion yuan, growth of 130% to 140% [3]. - Guolian Minsheng: Net profit of approximately 1.129 billion yuan, growth of 1183% [4]. Group 2: Market Dynamics - The brokerage sector has seen significant inflows of capital, with 1.253 billion yuan of leveraged funds net buying into the non-banking sector since July, ranking eighth among industry sectors [5]. - Analysts from various brokerages are optimistic about the brokerage sector, citing a stable bottom in the capital market and the potential for upward breakthroughs in equity markets [5]. - The current market rally is characterized by internal momentum rather than concentrated policy support, indicating a self-driven upward trend in the index due to sustained inflows of incremental capital [5].

Group 1 - The company expects a positive net profit for the period from January 1, 2025, to June 30, 2025, indicating a significant improvement in performance [1] - The company has communicated with its accounting firm regarding the earnings forecast, and there are no disagreements on the forecast [1][2] - The substantial growth in performance is attributed to increased fair value changes and investment income, with non-recurring gains expected to positively impact net profit by approximately 114.50 million yuan, compared to a loss of 274.77 million yuan in the same period of 2024 [2]

证券代码:000623 证券简称:吉林敖东 公告编号:2025-035 吉林敖东药业集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 预计净利润为正值且属于下列情形之一： ?扭亏为盈 ?同向上升 ?同向下降 项 目 本期报告 上年同期 归属于上市公司 盈利：123,616.05万元—128,990.66万元 盈利：53,746.11 万元 股东的净利润 比上年同期增长：130.00%—140.00% 扣除非经常性损 盈利：112,166.28万元—117,540.89万元 盈利：81,223.02 万元 益后的净利润 比上年同期增长：38.10%—44.71% 基本每股收益 盈利：1.05元/股—1.10元/股 盈利：0.46元/股 二、与会计师事务所沟通情况 公司已就业绩预告有关事项与会计师事务所进行了预沟通，公司与会计师事 务所在业绩预告方面不存在分歧。本次业绩预告未经过注册会计师预审计。 三、业绩变动原因说明 报告期内，公司围绕市值管理，聚焦医药主业，持续提升经营质量，积极践 行"专注于人、专精于药"的企业价值观，实 ...

吉林敖东（000623）公告，预计2025年1月1日至2025年6月30日归属于上市公司股东的净利润为12.36亿 元—12.9亿元，比上年同期的5.37亿元增长130.00%—140.00%。扣除非经常性损益后的净利润为11.22亿 元—11.75亿元，比上年同期的8.12亿元增长38.10%—44.71%。基本每股收益为1.05元/股—1.1元/股。 ...

证券代码:000623 证券简称:吉林敖东 公告编号:2025-035 吉林敖东药业集团股份有限公司 2025年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间 2025年1月1日至2025年6月30日 2、业绩预告情况 预计净利润为正值且属于下列情形之一： 扭亏为盈 同向上升 同向下降 | 项 目 | 本期报告 | 上年同期 | | --- | --- | --- | | 归属于上市公司 股东的净利润 | 盈利：123,616.05万元—128,990.66万元 | 盈利：53,746.11 万元 | | | 比上年同期增长：130.00%—140.00% | | | 扣除非经常性损 益后的净利润 | 盈利：112,166.28万元—117,540.89万元 | 盈利：81,223.02 万元 | | | 比上年同期增长：38.10%—44.71% | | | 基本每股收益 | 盈利：1.05元/股—1.10元/股 | 盈利：0.46元/股 | 公司已就业绩预告有关事项与会计师事务所进行了预沟通，公司与会 ...

Group 1 - Jilin Aodong (000623) participated in an investor relations event to enhance communication between investors and the company, showcasing its business scope which includes traditional Chinese medicine, chemical drugs, and health products [1] - The company has 628 production approval numbers, with 315 for traditional Chinese medicine, and aims to leverage its brand and product quality to enhance market value and sales of key products [1] - Jilin Aodong plans to cultivate multiple core products with over 100 million yuan in sales and accelerate the development of strategic products with a market potential of 10 billion yuan [1] Group 2 - The Yanbian Pharmaceutical project has completed several production facilities, which passed GMP compliance checks and are now contributing to revenue [2] - In 2024, the health business is expected to generate 212 million yuan in sales, accounting for 8.13% of total revenue, with over 200 health products produced and sold [2] - The company has 22 registered health food certificates and 85 filing certificates, with 43 products generating over 1 million yuan in sales [2] Group 3 - Jilin Aodong is enhancing brand awareness through diverse marketing strategies, including e-commerce and social media platforms like Douyin [3] - The company is focusing on the core value of traditional Chinese medicinal materials and aims to develop high-value projects through research and innovation [3] - The health product development system is driven by consumer health trends, emphasizing research and development of functional health products [3] Group 4 - The company is investing in core quality long-term equity securities and related pharmaceutical companies, collaborating with various funds to invest in biopharmaceuticals and internet healthcare [4] - Jilin Aodong aims to strengthen its research capabilities through indirect investments in distinctive and competitive biopharmaceutical projects [4] - The company is optimizing its financial asset allocation to create a positive cycle of financial capital supporting real industry growth [4]

Group 1: Company Overview and Business Focus - Jilin Aodong Pharmaceutical Group Co., Ltd. focuses on the pharmaceutical industry, including traditional Chinese medicine, chemical drugs, and health products [2][3] - The company has 628 production approval numbers, with 315 for traditional Chinese medicine and 525 for traditional Chinese medicine formula granules [3] - The company aims to enhance its core products, such as Anshen Bnnao Liquid and Xiaoer Chaigui Oral Liquid, to achieve high-quality development and cultivate multiple billion-yuan core products [3] Group 2: Financial Performance and Shareholder Returns - The company has implemented a cash dividend policy for 17 consecutive years, with a total cash dividend of 4.505 billion yuan [3] - A three-year shareholder return plan (2024-2026) aims to increase dividend frequency and optimize the dividend rhythm, ensuring stable and reasonable returns for shareholders [3] Group 3: Health Products and Market Strategy - In 2024, the health business generated sales revenue of 212.13 million yuan, accounting for 8.13% of total revenue [5] - The company produces over 200 health products, with 43 single products generating sales revenue exceeding one million yuan [5] - The company is enhancing its marketing strategies through e-commerce channels, including short videos and live broadcasts, to boost brand awareness and sales [5] Group 4: Research and Development Initiatives - The company is focusing on traditional Chinese medicine classic formulas and formula granules, with production facilities for these products already operational [4] - The company is committed to developing high-value projects using traditional Chinese medicinal materials, such as ginseng and deer antler, to meet the growing health consumption trends [5] Group 5: Investment Strategy - The company is shifting its investment focus towards the pharmaceutical industry chain and innovative pharmaceutical enterprises, including biotechnology companies [5] - Collaborations with various funds aim to invest in distinctive and competitive biopharmaceutical projects, enhancing the company's research capabilities [5]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has announced its 2024 annual cash dividend plan, which includes a total cash distribution of 351,714,476.10 yuan, with a dividend of 3.00 yuan per 10 shares for eligible shareholders [2][3][7]. Summary by Sections Dividend Distribution Plan - The 2024 annual cash dividend plan was approved at the shareholders' meeting on May 23, 2025, with a total share capital of 1,195,895,387 shares, excluding 23,513,800 shares held in the company's repurchase account, resulting in a base of 1,172,381,587 shares for the cash dividend distribution [3][4]. - The cash dividend distribution will be 3.00 yuan per 10 shares (before tax), with a total cash distribution amounting to 351,714,476.10 yuan [3][7]. Dividend Payment Details - The cash dividend will be distributed on July 9, 2025, with the record date set for July 8, 2025 [8][9]. - The cash dividends will be directly credited to the shareholders' accounts through their securities companies [9][10]. Taxation Information - Different tax rates will apply based on the type of shares held, with specific provisions for Hong Kong investors and domestic investors [8]. - The company will not withhold individual income tax at the time of distribution; instead, it will be calculated based on the holding period when shares are sold [8]. Adjustments and Calculations - The actual cash dividend amount is calculated based on the total shares eligible for distribution multiplied by the distribution ratio, resulting in a per-share cash dividend of approximately 0.2941013 yuan after the distribution [2][11]. - The ex-dividend price will be adjusted accordingly, calculated as the closing price on the record date minus the per-share cash dividend [11].

证券代码：000623 证券简称：吉林敖东 公告编号：2025-034 吉林敖东药业集团股份有限公司 2024年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 公司2024年度利润分配方案已获公司于2025年5月23日召开的2024年度股东 大会审议通过，详见公司于2025年5月24日在《证券时报》《上海证券报》《中 国证券报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）披露的《2024 年度股东大会决议公告》（公告编号：2025-029）。现将分红派息事宜公告如下： 一、股东大会审议通过利润分配方案情况 1．公司于 2025 年 5 月 23 日召开的 2024 年度股东大会审议通过了公司 2024 年度现金分红方案：以 2025 年 3 月 31 日的总股本 1,195,895,387 股扣除公司股 票回购专用证券账户上的股份 23,513,800 股后的 1,172,381,587 股为基数，向 全体股东每 10 股派发现金股利 3.00 元（含税），预计分派现金 351,714,476.1 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 吉林敖东药业集团股份有限公司（以下简称"公司"）接到股东敦化市金诚 实业有限责任公司（以下简称"金诚公司"）函告，获悉金诚公司所持有公司的 部分股份办理质押及解除质押手续，具体事项如下： （一）股东股份质押 1、股东股份质押基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次质押 | 占其所持 | 占公司总 | 是否 | 是否为 | | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | 数量(万 | 股份比例 | 股本比例 | 为限 | 补充质 | 质押起始日 | 质押到期日 | 质权人 | 用途 | | | 一致行动人 | 股) | | | 售股 | 押 | | | | | | 敦化市金 诚实业有 | | | | | | | 2025 年 6 月 | 质押期限至 其办理解除 | 上海海通 证券资产 | 经营 | | | 是 | 1,093.75 | 3 ...